

**National Cancer Institute
Clinical Trials and Translational Research Advisory Committee**

Ad Hoc Working Group on Cancer Screening Trials

The Clinical Trials and Translational Research Advisory Committee (CTAC) will convene a Working Group to provide general guidance to the NCI regarding cancer screening trials. The Working Group's charge will be to advise on the real-world impact of the COVID-19 pandemic on screening trials; on scientific questions that may be answered; and on strategies and timeline for their completion. They may address early detection, screening, imaging, clinical trials design, and other domains. An example of such a cancer screening trial is the Tomosynthesis Mammographic Imaging Screening Trial (TMIST), which is a large, randomized breast cancer screening study launched in July 2017, whose main goal is to evaluate whether tomosynthesis reduces the incidence of advanced cancers, which are intended to be a shorter term surrogate for mortality.

Working Group membership will include select CTAC members, as well as other individuals with expertise relevant to the cancer type(s) under study in the cancer screening trial.

The Working Group will advise the CTAC and the NCI Director.